Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Faron Pharmaceuticals Oy (FARN.LN)

Faron Pharmaceuticals Oy (FARN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Faron Pharmaceuticals Oy Joukahaisenkatu 6 B Turku 20520 FIN

https://www.faron.com P: 358-246-9515 F: 358-246-9515

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

Key Statistics

Overview:

Market Capitalization, $K 61,944
Shares Outstanding, K 115,784
% of Insider Shareholders 3.94%
% of Institutional Shareholders 5.27%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -25,920 K

Growth:

1-Year Return -67.75%
3-Year Return -84.00%
5-Year Return -84.00%
5-Year Revenue Growth 0.00%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.27
Dividend Payout Ratio 0.00%

FARN.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % N/A
Return-on-Assets % -119.80%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book N/A
Book Value/Share -0.12
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar